LinkedIn Icon
April 22-25, 2019 | Boston, MA

60+ Expert Speakers ♦ 4 Days  3 Streams ♦ 6 Workshops  Seminar Day ♦ 15+ Hours of Networking

Join the world’s largest meeting of non-alcoholic steatohepatitis stakeholders at industry’s most comprehensive NASH drug development conference: the 3rd Annual NASH Summit (April 22-25 2019, Boston, MA).

Across 4 days of focused seminars and parallel learning tracks, the 3rd Annual NASH Summit will cover every element of NASH drug development from early discovery to late-stage clinical development and commercialization. Providing an unparalleled learning and networking experience; this exclusive forum is the unrivaled opportunity to network with 300 drug developers from 140 organizations and accelerate the development of your NASH candidate pipeline.

Be at the forefront of the insights from 60+ leading experts as they share their learnings on:

  • Commercialization challenges, the payers perspective and the investors’ criteria for business in the current and future NASH market
  • The non-invasive diagnostics landscape and regulatory considerations on biomarker adoption for clinical trials
  • Computational methods and artificial intelligence to increase the efficiency of drug development
  • Scientific rationale of combinational therapeutics as the necessary treatment strategy for NASH to inform pairing decisions
  • Identification and recruitment of “high risk” patients needed to optimize clinical success and demonstrate sufficient efficacy

With 60+ experts on the speaking faculty due to be released save dates for the definitive congress in the NASH conference calendar, and register your interest to be the first to receive the finalized program!

“Well planned, and executed. Top notch organization. Gold standard of focused conferences.”
BioTelemetry Research

“Best meeting for industries and valuable information. This meeting makes my understanding for current situation and future perspectives deeper.”
Shionogi Co & Ltd

"An excellent opportunity to find out what other pharma are doing and what’s emerging. Very valuable."
AstraZeneca